Please Follow us on Truth Social, X , Youtube , Minds, Telegram, Rumble, GETTR, Gab
Treating cancer is big business and one that makes the big pharmaceutical companies massive amounts of cash. In 2024 alone, cancer treatments generated at least $200 billion in worldwide sales for the pharmaceutical industry. This is more than generated by the booming obesity drug rush.
Unfortunately, according to a Bloomberg analysis, fewer than half of treatments they reviewed — some of which have painful side effects — have been shown to extend patients’ lives.
Given the massive profit motive it shouldn’t be surprising that big pharma has shown zero interest in low-cost cancer treatments. Indeed, off-label use of of anti-parasitic drugs like ivermectin and mebendazole have demonstrated highly promising anti-cancer activity in preclinical models. But despite compelling…




